浙江巨化股份有限公司 股票简称：巨化股份 股票代码：600160 公告编号：临 2025－35 2025 年上半年主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江巨化股份有限公司（以下简称"公司"）根据《上海证券交易所上市公司 自律监管指引第 3 号——行业信息披露（第十三号化工）》有关规定，将公司 2025 年上半年主要经营数据披露如下： | 主要产品 | 产量 | 同比 | 外销量 | 同比 | 营业收入 | 同比 | | --- | --- | --- | --- | --- | --- | --- | | | 吨 | % | 吨 | % | 万元 | % | | 氟化工原料 | 602145.62 | 11.44 | 187526.53 | 11.72 | 68059.20 | 23.16 | | 制冷剂 | 285057.83 | -5.12 | 154588.31 | -4.19 | 608652.07 | 55.09 | | 含氟聚合物材料 | 69098.79 | 8.49 | 22 ...

5月26日，青岛国恩科技股份有限公司（以下简称：国恩股份 002768．SZ）发布公告称，公司于2025年5月26日召开董事会和监事 会，审议通过发行H股股票并在香港联交所主板挂牌上市的议案。公司计划通过发行境外上市外资股（H股）股票，打造国际化资本 运作平台，加快构建国内国际双循环格局。 根据公告披露，国恩股份本次拟发行的H股股数不超过本次发行后公司总股本的15％（超额配售权行使前），募集资金在扣除相关发 行费用后，将全部用于建设香港区域总部平台、科创研发投入、新增产能布局及战略性投资并购、补充运营资金等用途。本次发行 并上市尚需提交股东大会审议，并取得相关监管机构的备案、批准或核准。公司正积极推进相关工作，具体细节尚需进一步商讨。 另外值得注意的是，同在5月26日，国恩股份还发布了一则人事变动公告，公告显示，董事会近日收到董事张世德及独立董事刘树艳 的辞职报告。其中张世德因个人原因辞去董事职务，辞职后将继续在公司下属子公司任职；刘树艳也因个人原因辞去独立董事职 务，及在董事会各委员会的职务。辞职后，二人均未持有公司股份，且其辞职不会影响董事会的法定人数。 2025年一季度报显示，国恩股份今年一季度营收为4 ...

在大化工产业领域，国恩股份全力打造以绿色石化材料、有机高分子改性材料、有机高分子复合材料为 主的三大业务引擎，多维度构建"新材料+"产业生态圈，不断完善大化工产业纵向一体化布局。 大健康产业领域，国恩股份子公司东宝生物专业从事明胶、胶原蛋白及其延伸品的研发、生产、销售， 为下游用户提供全面系统的产品及服务方案，产品运营方式分为To B端业务和To C端业务。在To B端业 务方面，主要包括明胶、代血浆明胶、空心胶囊、胶原蛋白等，主要应用于药用辅料、医用胶原、营养 大健康市场、美妆、医疗医美、新材料应用等领域；在To C端产品方面，拥有以天然胶原蛋白肽为基础 成分的"胶原+"系列营养健康品、美妆产品等，能够满足不断发展的健康市场需求。 国恩股份（002768）5月26日晚间公告，公司拟发行H股股票并申请于香港联交所主板挂牌上市。 国恩股份表示，赴港上市是为深入推进公司全球化战略布局，打造国际化资本运作平台，加快构建国内 国际双循环格局，进一步助推公司产业全球化布局升维。公司将充分考虑现有股东的利益和境内外资本 市场的情况，在股东大会决议有效期内(即经公司股东大会审议通过之日起18个月或同意延长的其他期 限)选择 ...

Investment Rating - The report maintains a "Buy" investment rating for the company [1] Core Views - The company has experienced significant growth in performance, benefiting from the improved market conditions for refrigerants [1] - The revenue for 2024 reached 24.462 billion yuan, a year-on-year increase of 18.43%, while the net profit attributable to shareholders was 1.960 billion yuan, up 107.69% year-on-year [1] - In Q4 2024, the company achieved a revenue of 6.556 billion yuan, representing a year-on-year increase of 41.21% and a quarter-on-quarter increase of 12.52% [1] Summary by Sections Revenue Growth - The main drivers of revenue growth in 2024 were the expansion of the consolidated reporting scope, increased production, and higher prices. The three main business segments—refrigerants, petrochemical materials, and basic chemical products—continued to contribute significantly [2] - Refrigerant production for the year was 591,400 tons, a year-on-year increase of 21.12%, with external sales of 353,000 tons, up 22.61% [2] - Petrochemical materials production was 607,100 tons, a year-on-year increase of 36.14%, with external sales of 522,100 tons, up 45.70% [2] - Basic chemical products and others produced 3.0402 million tons, a year-on-year increase of 12.90%, with external sales of 1.7852 million tons, up 12.03% [2] Cost Management - The company reduced its sales expense ratio primarily due to decreased leasing costs. The sales/management/financial/R&D expense ratios changed by -0.18%/+0.06%/+0.28%/-0.54% year-on-year [3] Strategic Initiatives - The company is accelerating the production of new projects and enhancing its global HFCs quota advantage to establish a leading position in the refrigerant market. It has successfully completed the acquisition of Feiyuan Chemical, integrating its annual production capacity of 80,000 tons of HFCs and related facilities [4] - The company has also added new products in fine chemicals, significantly increasing the business proportion of fluorinated refrigerants and fine chemical products [4] - The annual production capacity of 85,700 tons of organic alcohol has been successfully put into operation, steadily increasing the domestic market share of organic alcohol products [4] Profit Forecast - The company’s profit forecast has been adjusted upwards, with expected net profits attributable to shareholders for 2025-2027 projected at 3.714 billion, 4.919 billion, and 6.050 billion yuan, respectively. The current stock price corresponds to P/E ratios of 18.5, 14.0, and 11.4 times for the respective years [9]

Investment Rating - The report maintains a "Buy" rating for the company [8] Core Views - The company reported a significant increase in net profit for Q1 2025, driven by the high demand for refrigerants, with a year-on-year growth of 161% [1] - The refrigerant market is expected to remain strong, supported by demand from downstream sectors such as air conditioning and automotive [4] - The company is projected to achieve net profits of 41 billion, 53 billion, and 61 billion RMB for the years 2025 to 2027, respectively, indicating a robust growth trajectory [5] Revenue and Profitability - In Q1 2025, the company achieved total revenue of 5.8 billion RMB, a year-on-year increase of 6% [1] - The company's gross profit margin improved to 28.4%, reflecting a year-on-year increase of 13.7 percentage points [3] - The earnings per share (EPS) for 2025 is estimated at 1.52 RMB, with a projected growth in EPS for the following years [5] Market Performance - The average price of refrigerants has increased, with R22, R32, R125, and R134a prices rising by 9%, 13%, 7%, and 11% respectively since the beginning of the year [4] - The company's market capitalization is approximately 68.47 billion RMB, with a target price set at 31.92 RMB [9] Segment Performance - The refrigerant segment saw a year-on-year sales increase of 4%, despite a seasonal decline in Q1 [2] - The fluoropolymer segment faced temporary pressure, with a year-on-year sales decline of 7% [2] - The basic chemical products segment benefited from improved caustic soda prices, leading to a revenue increase of 7% year-on-year [3]

事件：公司发布2024 年年报，公司2024 年实现营收244.62 亿元，同比增长18.43%，归母净利润19.6 亿 元，同比增长107.69%，其中四季度实现营收65.56亿元，同比增长41.21%，归母净利润7.02 亿元，同比 增长256.83%。 2024 年取得亮眼成绩主要是由于制冷剂板块贡献。公司主要产品市场结构性分化突出。公司第二、三 代氟制冷剂在生产配额制下，供需格局、竞争格局、竞争秩序优化，下游需求改善等，产品价格合理性 回归上行，涨幅较大；非制冷剂化工产品总体"供强需弱"，竞争激烈，价格下行。随着制冷剂产品价格 回升，公司制冷剂业务在主营业务结构、盈利结构中的占比大幅提升。 公司制冷剂业务因产品价格上行的增利影响大于公司非制冷剂业务因价格下行的减利影响。从经营数据 上来看，制冷剂营收贡献最大，增速也较快，同比增长62.6%，含氟精细化学品虽然占比较小，但是增 速最快，达到99.48%，除此之外氟化工原料和石化材料板块营收也取得正增长，可以说公司2024 年业 绩取得如此亮眼成绩主要依靠制冷剂板块。公司原材料市场局部价格坚挺，萤石、无水氟化氢、甲醇、 苯、硫磺、液氯、甘油、丙酮、环己酮等 ...

股票简称：巨化股份 股票代码：600160 公告编号：临 2025－11 浙江巨化股份有限公司 2025 年 1-3 月主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江巨化股份有限公司（以下简称"公司"）根据《上海证券交易所上市公司 自律监管指引第 3 号——行业信息披露（第十三号化工）》有关规定，将公司 2025 年 1-3 月主要经营数据披露如下： 【注】： 1、同比：指报告期与上年同期相比； 2、外销量低于产量，主要为部分产品作为内部下游产品原料所致； 3、基础化工产品中不含乙炔气、氢气、香精、冷冻油及其他非主要产品（下同）； 4、致冷剂（含全部品种）产量含混配致冷剂产量,产量大于销量主要为部分致冷剂用于公司混配致冷剂原料 所致。 二、主要产品和原材料的价格变动情况 第 1 页 共 3 页 主要产品 产量 同比 外销量 同比 营业收入 同比 吨 % 吨 % 万元 % 氟化工原料 292299.91 13.04 86881.55 11.07 32583.03 26.90 致冷剂 143563.6 ...